SPRO

SPRO's headline numbers look deceptively pristine — 50.2% operating margin, 68.1% net margin, ROE 14.5%, liabilities/equity of just 0.17x, and a P/E of 14.7 — but this is a clinical-stage biopharma with 'no products approved for sale.' The FY2025 revenue of $12.6M (+3,292% YoY) and $8.57M net income are milestone and collaboration revenue recognized from the GSK license, not durable product sales. The tell is the revenue/net-income history: net income swung -$89.8M → +$22.8M → -$68.6M → +$8.57M in four years, and despite the reported 2025 'profit,' operating cash flow was still -$12.6M. So the earnings-based multiples are meaningless; you are pricing an option on one drug, not a profit stream. On a P/S of 10.1x and ~2.2x book, the market is paying for tebipenem, not for what's on the income statement.

The entire thesis now rides on a single asset. The 10-K is explicit: SPR206 development ceased (March 2025) and SPR720 oral ceased (November 2025), leaving the company 'substantially dependent on our tebipenem program and our collaboration with GSK.' That partner controls the outcome — GSK can terminate the license on notice, on breach, or on a Spero bankruptcy, and on a change of control GSK can assume US development with no further milestones payable to Spero. So even a clinical success can be diluted by the very structure that de-risked the balance sheet. The company also flags it will 'need additional funding' beyond its current plan and may finance through equity offerings — a dilution risk sitting on top of a $451M accumulated deficit.